Delving into the Latest Updates on Sosei R&D Ltd. with Synapse

Overview

Tags

Nervous System Diseases

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Nervous System Diseases	2

Top 5 Drug Type	Count

Small molecule drug	2

Top 5 Target	Count

CGRP x CGRP receptor	2

Nefopam is a modestly potent but non-selective inhibitor of serotonin and noradrenaline reuptake (S+NRI).In addition the mol. possesses significant central antihistamine (H1 antagonist) activity.Nefopam (1) suffers from extensive first pass metabolism to an inactive N-demethyl metabolite, lowering bioavailability and limiting efficacy in animal models.The discovery of novel anti-emetic pharmacol. in nefopam (1) has led Arakis to undertake a property driven medicinal chem. program aimed at improving the potency and selectivity of the template while enhancing pharmacokinetics.ARAK0029 (2) is a potent selective serotonin reuptake inhibitor (SSRI), devoid of antihistamine activity.The compound is primarily metabolized by O-demethylation to an -active′ metabolite increasing the pharmacodynamics of the template.A second series based on ARAK0051 (3) are representative of a potent class of S+NRI′s.Strategies to improve pharmacokinetics and eliminate CYP2D6 activity will be presented and exemplified by derivatives from a second wave of medicinal chem.Lead compounds are now devoid of both H1 antagonist activity and the CYP2D6 inhibition present in the parent mol.

100 Deals associated with Sosei R&D Ltd.

Login to view more data

100 Translational Medicine associated with Sosei R&D Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 23 Dec 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

2

16

Other

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

HTL-0029881 ( CGRP x CGRP receptor )	Migraine Disorders More	Preclinical
HTL0029882 ( CGRP x CGRP receptor )	Migraine Disorders More	Preclinical
SRSC-371	Epilepsy More	Discontinued
SRSS-021 ( 5-HT3 receptor )	Chemotherapy-induced nausea and vomiting More	Discontinued
AD-529 ( NMDA receptor )	Neuralgia More	Discontinued